ArticleBone marrow transplantation2006
Hematopoietic stem cell transplantation for natural killer-cell lineage neoplasms.
Article in Bone marrow transplantation, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Allogeneic Hematopoietic Stem Cell Transplantation in Extranodal Natural Killer/T-cell LymphomaTurkish journal of haematology : official journal of Turkish Society of Haematology · 2021Pooled it
- Combination of anti-PD-1 antibody with P-GEMOX as a potentially effective immunochemotherapy for advanced natural killer/T cell lymphoma.Signal transduction and targeted therapy · 2020Trial
- Long-term Outcome of Extranodal NK/T Cell Lymphoma Patients Treated With Postremission Therapy Using EBV LMP1 and LMP2a-specific CTLs.Molecular therapy : the journal of the American Society of Gene Therapy · 2015Trial
- T-cell-replete haploidentical stem cell transplantation is highly efficacious for relapsed and refractory childhood acute leukaemia.Transfusion medicine (Oxford, England) · 2014Trial
- Pediatric extranasal, EBV-negative, extranodal natural killer/T-cell lymphoma; case report.Pathology oncology research : POR · 2026Article
- High-risk extranodal natural killer/T-cell lymphoma patients could benefit more from allogeneic hematopoietic stem cell transplantation as consolidation: A real-world multicenter analysis in China.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025Article
- Article
- Modified SMILE (mSMILE) is active in the treatment of pediatric Epstein-Barr virus-associated natural killer/T-cell lymphoma: a single center experience, case series.Translational pediatrics · 2024Article
- Aggressive natural killer/T-cell lymphoma masquerading as acute orbital hemorrhage: a case report.International journal of clinical and experimental pathology · 2020Article
- Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: Basic Science and Clinical Progress.Frontiers in pediatrics · 2019Review
- Article
- NK/T Cell Lymphoma: Updates in Therapy.Current hematologic malignancy reports · 2018Review
- Blastic plasmacytoid dendritic cell neoplasm in children: A review of two cases.Molecular and clinical oncology · 2017Article
- Clinical features and treatment outcomes of blastic plasmacytoid dendritic cell neoplasm: a single-center experience in Korea.The Korean journal of internal medicine · 2017Article
- Allogeneic Hematopoietic Cell Transplantation for Aggressive NK Cell Leukemia. A Center for International Blood and Marrow Transplant Research Analysis.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2017Article
- T-cell lymphomas, a challenging disease: types, treatments, and future.International journal of clinical oncology · 2017Review
- Blastic plasmacytoid dendritic cell neoplasm: challenges and future prospects.Blood and lymphatic cancer : targets and therapy · 2017Review
- Treatment outcomes of and prognostic factors for definitive radiotherapy with and without chemotherapy for Stage I/II nasal extranodal NK/T-cell lymphoma.Journal of radiation research · 2017Article
- CD56-Negative Aggressive NK Cell Leukemia Relapsing as Multiple Cranial Nerve Palsies: Case Report and Literature Review.Case reports in hematology · 2017Article
- Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases.Current hematologic malignancy reports · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neoplasms of natural killer (NK)-lineage are rare. Their prognosis is generally poor except for cases of solitary nasal NK-cell lymphoma. The NK-cell Tumor Study Group performed a survey in Japan on patients diagnosed between 1994 and 1998. Of 228 patients selected for analysis, 40 underwent HSCT (15 allografts and 25 autografts). The underlying diseases were myeloid/NK cell precursor acute leukemia (n = 4), blastic NK-cell lymphoma (n = 11), aggressive NK-cell leukemia (n = 3), and nasal-type extranodal NK-cell lymphoma (n = 22). At the time of HSCT, 22 patients were in complete remission (CR), 11 were in relapse, and seven were primary refractory. All patients received myeloablative conditioning regimens including total-body irradiation. Sixteen died of disease progression, and six of treatment-related causes. Overall, 4-year survival was 39% with a median follow-up of 50 months; this was significantly better than that of patients who did not undergo HSCT (21%, P = 0.0003). For patients transplanted in CR, the 4-year overall survival was 68%, which was significantly better than that of patients who went into CR but did not undergo HSCT (P = 0.03). These findings suggest that the HSCT is a promising treatment strategy for NK-cell lineage.
Indexed as
Identifiers
16400344What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.